|
1
|
Parkkila S: An overview of the
distribution and function of carbonic anhydrases in mammals. The
Carbonic Anhydrases: New Horizons. Chegwidden WR, Carter N and
Edwards Y: Birkhauser Verlag; Basel: pp. 76–93. 2000
|
|
2
|
Wingo T, Tu C, Laipis PJ and Silverman DN:
The catalytic properties of human carbonic anhydrase IX. Biochem
Biophys Res Commun. 288:666–669. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Opavsky R, Pastorekova S, Zelnik V, et al:
Human MN/CA9 gene, a novel member of the carbonic anhydrase family:
structure and exon to protein domain relationships. Genomics.
33:480–487. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Potter C and Harris AL: Hypoxia inducible
carbonic anhydrase IX, marker of tumour hypoxia, survival pathway
and therapy target. Cell Cycle. 3:164–167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hussain SA, Ganesan R, Reynolds G, et al:
Hypoxia-regulated carbonic anhydrase IX expression is associated
with poor survival in patients with invasive breast cancer. Br J
Cancer. 96:104–109. 2008. View Article : Google Scholar
|
|
7
|
Ord JJ, Agrawal S, Thamboo TP, et al: An
investigation into the prognostic significance of necrosis and
hypoxia in high grade and invasive bladder cancer. J Urology.
178:677–682. 2007. View Article : Google Scholar
|
|
8
|
Le QT, Kong C, Lavori PW, et al:
Expression and prognostic significance of a panel of tissue hypoxia
markers in head-and-neck squamous cell carcinomas. Int J Radiat
Oncol Biol Phys. 69:167–175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Driessen A, Landuyt W, Pastorekova S, et
al: Expression of carbonic anhydrase IX (CAIX), a hypoxia-related
protein, rather than vascular-endothelial growth factor (VEGF), a
pro-angiogenic factor, correlates with an extremely poor prognosis
in esophageal and gastric adenocarcinomas. Ann Surg. 243:334–340.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swinson DE, Jones JL, Richardson D, et al:
Carbonic anhydrase IX expression, a novel surrogate marker of tumor
hypoxia, is associated with a poor prognosis in non-small-cell lung
cancer. J Clin Oncol. 21:473–482. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robertson N, Potter C and Harris AL: Role
of carbonic anhydrase IX in human tumor cell growth, survival, and
invasion. Cancer Res. 64:6160–6165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brizel DM, Dodge RK, Clough RW and
Dewhirst MW: Oxygenation of head and neck cancer: changes during
radiotherapy and impact on treatment outcome. Radiother Oncol.
53:113–117. 1999. View Article : Google Scholar
|
|
13
|
Hockel M, Schlenger K, Aral B, et al:
Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515.
1996.PubMed/NCBI
|
|
14
|
Zeng L, Ou G, Itasaka S, et al: TS-1
enhances the effect of radiotherapy by suppressing
radiation-induced hypoxia-inducible factor-1 activation and
inducing endothelial cell apoptosis. Cancer Sci. 99:2327–2335.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zaffaroni N, Fiorentini G and De Giorgi U:
Hyperthermia and hypoxia: new developments in anticancer
chemotherapy. Eur J Surg Oncol. 27:340–342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamazaki Y, Kunimoto S and Ikeda D:
Rakicidin A: a hypoxia-selective cytotoxin. Biol Pharm Bull.
30:261–265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raleigh JA, Dewhirst MW and Thrall DE:
Measuring tumor hypoxia. Semin Radiat Oncol. 6:37–45. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mees G, Dierckx R, Vangestel C and Van de
Wiele C: Molecular imaging of hypoxia with radiolabelled agents.
Eur J Nucl Med Mol Imaging. 36:1674–1686. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Machulla HJ: Imaging of Hypoxia-Tracer
Developments. Kluwer Academic Publishers; Dordrecht: pp. 1–18.
1999
|
|
20
|
Wiebe LI and McEwan AJB: Scintigraphic
imaging of focal hypoxic tissue: development and clinical
applications of 123I-IAZA. Braz Arch Biol Technol.
45:89–102. 2002. View Article : Google Scholar
|
|
21
|
Wiebe LI: PET radiopharmaceuticals for
metabolic imaging in oncology. PET and Molecular Imaging: State of
the Art and Future Perspectives. Tamaki Y and Kuge Y:
(International Congress Series 1264C). Elsevier; Amsterdam: pp.
53–76. 2003
|
|
22
|
Graham MM, Peterson LM, Link JM, et al:
Fluorine-18-fluoromisonidazole radiation dosimetry in imaging
studies. J Nucl Med. 38:1631–1636. 1997.PubMed/NCBI
|
|
23
|
Doss M, Zhang JJ, Bélanger MJ, et al:
Biodistribution and radiation dosimetry of the hypoxia marker
18F-HX4 in monkeys and humans determined by using
whole-body PET/CT. Nucl Med Commun. 31:1016–1024. 2010.PubMed/NCBI
|
|
24
|
Brouwers AH, Buijs WC, Mulders PF, et al:
Radioimmunotherapy with [131I]cG250 in patients with
metastasized renal cell cancer: dosimetric analysis and immunologic
response. Clin Cancer Res. 11:7178–7186. 2005. View Article : Google Scholar
|
|
25
|
Li Y, Wang H, Oosterwijk E, et al:
Antibody-specific detection of CAIX in breast and prostate cancers.
Biochem Biophys Res Commun. 28:488–492. 2009. View Article : Google Scholar
|
|
26
|
Oosterwijk-Wakka JC, Boerman OC, Peter FA,
Oosterwijk M and Oosterwijk E: Application of monoclonal antibody
G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int
J Mol Sci. 14:11402–11423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Steffens MG, Boerman OC, Oyen WJG, et al:
MN/CA IX/G250 as a potential target for immunotherapy of renal cell
carcinomas. Br J Cancer. 81:741–746. 1999. View Article : Google Scholar
|
|
28
|
Kerbel R and Folkman J: Clinical
translation of angiogenesis inhibitors. Nat Rev Cancer. 2:727–739.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Povoski SP, Hall NC, Murrey DA Jr, et al:
Multimodal imaging and detection strategy with 124 I-Labeled
chimeric monoclonal antibody cG250 for accurate localization and
confirmation of extent of disease during laparoscopic and open
surgical resection of clear cell renal cell carcinoma. Surg Innov.
20:59–69. 2013. View Article : Google Scholar :
|
|
30
|
Ahlskog JK, Schliemann C, Mårlind J, et
al: Human monoclonal antibodies targeting carbonic anhydrase IX for
the molecular imaging of hypoxic regions in solid tumours. Br J
Cancer. 101:645–657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carlin S, Khan N, Ku T, et al: Molecular
targeting of carbonic anhydrase IX in mice with hypoxic HT29
colorectal tumor xenografts. PLoS One. 5:e108572010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hoeben BA, Kaanders JH, Franssen GM, et
al: PET of hypoxia with 89Zr-labeled
cG250-F(ab′)2 in head and neck tumors. J Nucl Med.
51:1076–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Askoxylakis V, Garcia-Boy R, Rana S, et
al: A new peptide ligand for targeting human carbonic anhydrase IX,
identified through the phage display technology. PLoS One.
5:e159622010. View Article : Google Scholar
|
|
34
|
Löfblom J, Feldwisch J, Tolmachev V, et
al: Affibody molecules: engineered proteins for therapeutic,
diagnostic and biotechnological applications. FEBS Lett.
584:2670–2680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nygren PÅ: Alternative binding proteins:
affibody binding proteins developed from a small three-helix bundle
scaffold. FEBS J. 275:2668–2676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Orlova A, Magnusson M, Eriksson TL, et al:
Tumor imaging using a picomolar affinity HER2 binding affibody
molecule. Cancer Res. 66:4339–4348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahlgren S and Tolmachev V: Radionuclide
molecular imaging using Affibody molecules. Curr Pharm Biotechnol.
11:581–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Baum RP, Prasad V, Muller D, et al:
Molecular imaging of HER2-expressing malignant tumors in breast
cancer patients using synthetic 111In- or
68Ga-labeled affibody molecules. J Nucl Med. 51:892–897.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sörensen J, Sandberg D, Sandström M, et
al: First-in-human molecular imaging of HER2 expression in breast
cancer metastases using the 111In-ABY-025 affibody
molecule. J Nucl Med. 55:730–735. 2014. View Article : Google Scholar
|
|
40
|
Tolmachev V, Hofstrom C, Malmberg J, et
al: HEHEHE-tagged affibody molecules may be purified by IMAC, are
conveniently labeled with
[99mTc(CO)3]+ and show improved
biodistribution. Bioconjug Chem. 21:2013–2022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Orlova A, Wållberg H, Stone-Elander S and
Tolmachev V: On the selection of a tracer for PET imaging of
HER2-expressing tumors: direct comparison of a
124I-labeled Affibody molecule and trastuzumab in a
murine xenograft model. J Nucl Med. 50:417–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Björkelund H, Gedda L, Barta P, Malmqvist
M and Andersson K: Gefitinib induces epidermal growth factor
receptor dimers which alters the interaction characteristics with
125I-EGF. PLoS One. 6:e247392011. View Article : Google Scholar
|
|
43
|
Wållberg H and Orlova A: Slow
internalization of anti-HER2 synthetic affibody monomer
111In-DOTA-ZHER2:342-pep2: implications for
development of labeled tracers. Cancer Biother Radiopharm.
23:435–442. 2008. View Article : Google Scholar
|
|
44
|
Kramer-Marek G, Kiesewetter DO, Martiniova
L, Jagoda E, Lee SB and Capala J:
[18F]FBEM-ZHER2:342-Affibody molecule-a new
molecular tracer for in vivo monitoring of HER2 expression by
positron emission tomography. Eur J Nucl Med Mol Imaging.
35:1008–1018. 2008. View Article : Google Scholar
|
|
45
|
Brouwers AH, van Eerd JE, Frielink C,
Oosterwijk E, Oyen WJ, Corstens FH and Boerman OC: Optimization of
radioimmunotherapy of renal cell carcinoma: labeling of monoclonal
antibody cG250 with 131I, 90Y,
177Lu, or 186Re. J Nucl Med. 45:327–337.
2004.PubMed/NCBI
|
|
46
|
Lawrentschuk N, Lee FT, Jones G,
Rigopoulos A, Mountain A, et al: Investigation of hypoxia and
carbonic anhydrase IX expression in a renal cell carcinoma
xenograft model with oxygen tension measurements and
124I-cG250 PET/CT. Urol Oncol. 29:411–420. 2011.
View Article : Google Scholar
|
|
47
|
Akurathi V, Dubois L, Celen S, et al:
Development and biological evaluation of
99mTc-sulfonamide derivatives for in vivo visualization
of CA IX as surrogate tumor hypoxia markers. Eur J Med Chem.
71:374–384. 2014. View Article : Google Scholar : PubMed/NCBI
|
